Agios Pharmaceuticals has seen its fair value estimate cut from roughly $42.33 to about $32.13 per share, as analysts recalibrate expectations following mixed clinical outcomes and a more uncertain ...
US FDA approves Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma: Princeton, New Jersey Saturday, December 6, 2025, 09:00 Hrs [IST] ...
The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback